Editorial commentary on the UK regulatory record
Semaglutide and liraglutide: the UK licensing and regulatory record
Oliver Mackman · Editorial director · Best Business Loans Ltd (16833937)
Last updated 2026-06-01
This page is editorial commentary on the UK regulatory record for two GLP-1 receptor agonist medicines licensed for weight management: semaglutide (marketed as Wegovy by Novo Nordisk) and liraglutide 3.0 mg (marketed as Saxenda by Novo Nordisk). It signposts the MHRA marketing authorisations, the relevant NICE technology appraisals (TA875, TA664), the SmPCs on the MHRA Products database, and the published trial documentation. Both are prescription-only medicines. PeptideClear does not publish branded efficacy comparisons or per-route POM prices and does not recommend a medicine for any individual. Any prescribing decision is between a patient and a UK-licensed prescriber.
AI-friendly summary · Semaglutide and liraglutide UK licensing
Semaglutide (Wegovy) and liraglutide 3.0 mg (Saxenda) are both GLP-1 receptor agonist medicines from Novo Nordisk, licensed in the UK for weight management and available prescription-only. This editorial page summarises the UK regulatory record: the MHRA marketing authorisations, NICE technology appraisals TA875 and TA664, and the published trial documentation. PeptideClear does not publish branded efficacy comparisons. Any prescribing decision rests with a UK-licensed prescriber.
Published trial documentation referenced on this page
- · STEP-1 (semaglutide, weight management, N Engl J Med 2021, PMID 33567185). The pivotal weight-management trial that supported the semaglutide weight-management indication.
- · SCALE Obesity and Prediabetes (liraglutide 3.0 mg, weight management, N Engl J Med 2015, PMID 26132939). The pivotal weight-management trial that supported the liraglutide 3.0 mg weight-management indication.
- · SELECT (semaglutide, cardiovascular outcomes in adults with overweight or obesity and established CV disease, N Engl J Med 2023, PMID 37952131). Basis for the cardiovascular outcome indication added to the semaglutide label.
Note: no published head-to-head randomised trial compares semaglutide and liraglutide on a weight-management endpoint. PeptideClear does not publish branded efficacy comparisons for these prescription-only medicines.
Reference table: the UK regulatory record
| Characteristic | Semaglutide | Liraglutide |
|---|---|---|
| Active molecule | Semaglutide | Liraglutide |
| UK marketing authorisation holder | Novo Nordisk (brand: Wegovy) | Novo Nordisk (brand: Saxenda) |
| Mechanism described in the literature | GLP-1 receptor agonist (longer-acting) | GLP-1 receptor agonist (shorter-acting) |
| Dosing frequency on the SmPC | Once-weekly subcutaneous injection | Once-daily subcutaneous injection |
| UK launch (weight-management indication) | 2022 | 2017 |
| Pivotal weight-management trial | STEP-1 | SCALE Obesity and Prediabetes |
| NICE technology appraisal | TA875 (semaglutide for weight management) | TA664 (liraglutide 3.0 mg for weight management) |
| NHS access framework (2026) | Restricted access under TA875. CV outcome indication broadens reimbursement on the CV-prevention route from April 2026. | Restricted access under TA664. Largely superseded in UK prescribing practice by longer-acting GLP-1 receptor agonists since 2023. |
| Storage (SmPC) | Refrigerated; in-use room-temperature limit set in the SmPC. | Refrigerated; in-use room-temperature limit set in the SmPC. |
| Legal status | Prescription-only medicine | Prescription-only medicine |
Sources: SmPC entries on the MHRA Products database and NICE technology appraisal documents (TA875, TA664). The position can change; always check the current SmPC.
What the literature and the UK regulatory record describe
Liraglutide 3.0 mg was the first daily GLP-1 receptor agonist licensed for weight management in the UK (Saxenda, 2017). Semaglutide (Wegovy) followed in 2022 as a once-weekly preparation in the same drug class. The published placebo-controlled trials describe different mean weight reductions for the two medicines, but no head-to-head trial compares them; PeptideClear does not publish branded efficacy comparisons for these prescription-only medicines.
Since 2023, UK prescribing observation suggests that semaglutide and tirzepatide have largely displaced liraglutide in private weight-management prescribing, reflecting the shift to once-weekly dosing on the SmPC. NHS access for both semaglutide and liraglutide is restricted under their respective NICE appraisals (TA875 and TA664) to defined BMI thresholds, comorbidity criteria, and specialist weight-management service settings.
Adverse-event profiles described in the SmPCs for both medicines are dominated by gastrointestinal events. The current SmPC entries on the MHRA Products database are the authoritative reference for the full list and frequency tables, and for storage, contraindications and warnings.
UK regulatory and access framework
- · Both medicines are prescription-only (POM) under the Human Medicines Regulations 2012. They may only be supplied against a prescription written by a UK-registered prescriber.
- · The MHRA is the UK regulator that holds the marketing authorisations. Current SmPCs and patient information leaflets are published on the MHRA Products database and emc.medicines.org.uk.
- · NICE technology appraisals TA875 (semaglutide) and TA664 (liraglutide) set the NHS eligibility criteria for each medicine.
- · The CMA, ASA and MHRA jointly regulate UK advertising of POM. Branded consumer-facing comparison advertising of POM is not permitted. This page is editorial commentary on the public regulatory record and does not advertise any product to any individual.
- · Suspected side effects can be reported through the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk.
UK MHRA-licensed routes that dispense these medicines
The following directories list UK clinics and pharmacies that operate under General Pharmaceutical Council registration and CQC regulation where applicable. They are listed for reference only. Inclusion is not an endorsement of any medicine for any reader. Cross-reference: semaglutide and tirzepatide editorial commentary.
- · UK clinic directory: clinician-led services operating under GPhC and (where applicable) CQC oversight.
- · UK pharmacy directory: GPhC-registered online pharmacies operating under the Human Medicines Regulations 2012.
- · NHS access notes: editorial summary of the NICE-defined NHS pathway.
This page is editorial commentary on the UK regulatory record. It is not medical advice and it does not recommend any medicine to any individual. Semaglutide and liraglutide are prescription-only medicines. The decision about whether either medicine is appropriate, and at what dose, is between a patient and a UK-licensed prescriber, who will refer to the current SmPC, the patient's clinical history, and the relevant NICE appraisal. Always read the patient information leaflet supplied with any prescribed medicine.